Photodynamic therapy is a new treatment modality for wet age-related macular degeneration (ARMD). GPs need to know when to refer suitable patients, as well as how to advise them on what is involved in treatment and the potential outcomes to be expected.
What is ARMD?
Age-related macular degeneration (ARMD) is a progressive disease of the central retina that results in deterioration of the central visual field. It affects approximately 2% of the population over 50 years of age, increasing to 18.5% among those 85 years of age or older.
The two types of ARMD are ‘dry’ (90% of cases) and ‘wet’ (10% of cases). The peripheral retina in both types tends to be spared, preserving side vision and therefore maintaining ambulatory vision.